The company is the first multi-site excipient supplier to achieve accreditation across production facilities.
Croda announced that all its global excipient manufacturing sites have completed EXCiPACT audit requirements and have been certified according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard. The certifications are given after manufacturing processes, quality systems, quality management, and storage and distribution facilities are inspected during audits.
"This achievement brings significant value to both Croda and our customers, reducing the audit burden on both sides whilst maintaining confidence in Croda's compliance to the demanding standards of the pharmaceutical industry. The certificate assures our customers that Croda manufactures and distributes pharmaceutical excipients to EXCiPACT good manufacturing (GMP) standards. It is a measure of excellence in quality and an assurance for our customers that they are always in receipt of material of the highest standards," said Dave Cherry, managing director of Croda’s Health Care business, in a press statement.
